Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit http://www.avanir.com. Avanir is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally, and its products are available in more than 80 countries worldwide. Avanir® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.
Parent Company
Otsuka Pharmaceutical
Aliso Viejo, US
Avanir Pharmaceuticals was founded in 1988 and is headquartered in Aliso Viejo, US
Report incorrect company information

Avanir Pharmaceuticals Office Locations

Avanir Pharmaceuticals has offices in Aliso Viejo, New York and Jersey
Aliso Viejo, US (HQ)
400 30 Enterprise
Show all (3)
Report incorrect company information

Avanir Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$30 m


Avanir Pharmaceuticals is a subsidiary of Otsuka Pharmaceutical

Avanir Pharmaceuticals Financials

USDFY, 2013FY, 2014


55.3 m271.9 m

Accounts Receivable

12.5 m22.8 m

Current Assets

71.8 m300.8 m
USDFY, 2013FY, 2014

Net Income

(75.5 m)(50.4 m)

Depreciation and Amortization

826.5 k1.4 m

Accounts Payable

2.9 m372 k
Show all financial metrics
Report incorrect company information